NCT06352632 ACT-GLOBAL Adaptive Platform Trial for Stroke
| NCT ID | NCT06352632 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | The George Institute |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2024-09-26 |
| Primary Completion | 2034-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 20,000 participants in total. It began in 2024-09-26 with a primary completion date of 2034-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.
Eligibility Criteria
Platform Inclusion Criteria: 1. Age ≥18 years 2. Clinical diagnosis of stroke Platform Exclusion Criteria: There are no platform level exclusion criteria Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.
Contact & Investigator
Craig Anderson, MD, PhD
PRINCIPAL INVESTIGATOR
The George Institute
Frequently Asked Questions
Who can join the NCT06352632 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06352632 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 20,000 participants.
Is NCT06352632 currently recruiting?
Yes, NCT06352632 is actively recruiting participants. Contact the research team at xchen@georgeinstitute.org.au for enrollment information.
Where is the NCT06352632 trial being conducted?
This trial is being conducted at Sydney, Australia, Calgary, Canada.
Who is sponsoring the NCT06352632 clinical trial?
NCT06352632 is sponsored by The George Institute. The principal investigator is Craig Anderson, MD, PhD at The George Institute. The trial plans to enroll 20,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.